Evidence map›Paper›PMID 19422394›Full record

ArticleBritish journal of pharmacology2009

Role of alpha 1- and beta 3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse.

Sotiria Bexis, James R Docherty

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Circulating Beta3-Adrenoreceptor as Novel Independent Biomarker for Risk Assessment in Neuroblastoma Patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Polycystic kidney disease strikes a nerve.Physiological reports · 2021
    Article
  9. Article
  10. Article
  11. Response gene to complement 32 suppresses adipose tissue thermogenic genes through inhibiting β3-adrenergic receptor/mTORC1 signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Article
  12. Article
  13. Article
  14. Blue light reduces organ injury from ischemia and reperfusion.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  15. Article
  16. The sympathetic nervous system is controlled by transient receptor potential vanilloid 1 in the regulation of body temperature.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015
    Article
  17. Catechol-o-methyltransferase and 3,4-({+/-})-methylenedioxymethamphetamine toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2014
    Article
  18. Article
  19. Review
  20. Subtypes of functional alpha1-adrenoceptor.Cellular and molecular life sciences : CMLS · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sotiria BexisDepartment of Physiology, Royal College of Surgeons in Ireland, Dublin, Ireland.
James R Docherty
Royal College of Surgeons in Ireland · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeWe have investigated the ability of the beta(3)-adrenoceptor antagonist 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4,-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol hydrochloride (SR59230A) to affect the hyperthermia produced by methylenedioxymethamphetamine (MDMA) in conscious mice and whether alpha(1)-adrenoceptor antagonist actions are involved. EXPERIMENTAL APPROACH: Mice were implanted with temperature probes under anaesthesia, and allowed 2 week recovery. MDMA (20 mg x kg(-1)) was administered subcutaneously 30 min after vehicle or test antagonist and effects on body temperature monitored by telemetry. KEY

resultsFollowing vehicle, MDMA produced a slowly developing hyperthermia, reaching a maximum increase of 1.8 degrees C at 130 min post injection. A low concentration of SR59230A (0.5 mg x kg(-1)) produced a small but significant attenuation of the slowly developing hyperthermia to MDMA. A high concentration of SR59230A (5 mg x kg(-1)) revealed a significant and marked early hypothermic reaction to MDMA, an effect that was mimicked by the alpha(1)-adrenoceptor antagonist prazosin. Functional and ligand binding studies revealed actions of SR59230A at alpha(1)-adrenoceptors. CONCLUSIONS AND IMPLICATIONS: 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4,-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol hydrochloride in high concentrations modulates the hyperthermic actions of MDMA in mice in two ways: by blocking an early alpha(1)-adrenoceptor-mediated component to reveal a hypothermia, and by a small attenuation of the later hyperthermic component which may possibly be beta(3)-adrenoceptor-mediated (this seen with the low concentration of SR59230A). Hence, the major actions of SR59230A in modulating the actions of MDMA on temperature involve alpha(1)-adrenoceptor antagonism.

Indexed as

Adrenergic beta-3 Receptor AntagonistsAnimalsBody TemperatureFeverIn Vitro TechniquesMaleMiceMice, Inbred C57BLN-Methyl-3,4-methylenedioxyamphetaminePropanolaminesProtein BindingRatsReceptors, Adrenergic, alpha-1Receptors, Adrenergic, beta-33-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalateAdrenergic beta-3 Receptor AntagonistsN-Methyl-3,4-methylenedioxyamphetaminePropanolaminesReceptors, Adrenergic, alpha-1Receptors, Adrenergic, beta-3

Identifiers

PMID19422394
PMCPMC2795232
OpenAlexW2029608095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.